Overview

Prostate cancer is the second most common cancer, after skin cancer, among men. It is the second leading cause of cancer death in the United States. This year, it is estimated that about 174,650 men in the United States will be diagnosed with prostate cancer and 31,620 men will die from this disease. Androgen deprivation therapy (ADT) aimed at lowering the level of androgens, is the standard of care for men with advanced prostate cancer. Newly diagnosed metastatic disease that has spread to other parts of the body and still responds to testosterone suppression therapy is called metastatic castration-sensitive prostate cancer (mCSPC). Androgen receptor inhibitors are currently being investigated in combination with ADT given the knowledge that deeper androgen signal inhibition results in further improved outcomes in mCSPC. With the recent drug approvals and updates to clinical practice guidelines, several knowledge, competence and performance gaps exist in the optimal management of mCSPC among oncology practitioners.

This education activity provides guidance on the optimal management of mCSPC and addresses strategies for translating clinical updates into new patient care strategies.

This activity was hosted by the Texas Society of Clinical Oncology (TxSCO)—a Chapter Member of the Association of Community Cancer Centers. 

Continuing Education

Emerging Therapies for the Management of Castration- Sensitive Prostate Cancer

April 16, 2021 | 12:00 - 1:00 PM CDT

This educational activity is jointly provided by AXIS Medical Education and the Association of Community Cancer Centers (ACCC).

This educational activity is supported by independent grants from Astellas and Pfizer, Inc.

Target Audience

The target audience for this initiative includes medical oncologists, urologic oncologists, urologists, oncology advanced practice providers (nurse practitioners, physician assistants), oncology pharmacists, oncology nurses, and other healthcare professionals (HCPs) involved in treating patients with prostate cancer.

Overview

Prostate cancer is the second most common cancer, after skin cancer, among men. It is the second leading cause of cancer death in the United States. This year, it is estimated that about 174,650 men in the United States will be diagnosed with prostate cancer and 31,620 men will die from this disease. Androgen deprivation therapy (ADT) aimed at lowering the level of androgens, is the standard of care for men with advanced prostate cancer. Newly diagnosed metastatic disease that has spread to other parts of the body and still responds to testosterone suppression therapy is called metastatic castration-sensitive prostate cancer (mCSPC). Androgen receptor inhibitors are currently being investigated in combination with ADT given the knowledge that deeper androgen signal inhibition results in further improved outcomes in mCSPC. With the recent drug approvals and updates to clinical practice guidelines, several knowledge, competence and performance gaps exist in the optimal management of mCSPC among oncology practitioners. Participants from previous Association of Community Cancer Centers (ACCC) educational programs revealed transitions of care, including communication between the numerous healthcare settings (52%), side effect management (45%), and keeping current on the latest treatment modalities (29%) as among the most commonly encountered challenges for practitioners.

This education activity will provide guidance on the optimal management of mCSPC to oncologists, urologists, oncology advanced practitioners and other members of the multidisciplinary cancer care team. The educational program will address some of the challenges in optimal sequencing of care in mCSPC and will provide an opportunity to discuss with leading oncology experts and colleagues how new research clinical updates can be translated into new patient care strategies.

Learning Objectives

At the end of this educational activity, participants should be able to:

  1. Describe current and emerging treatment options in mCSPC.
  2. Employ strategies for optimal management of treatment-related adverse events experienced by patients treated for mCSPC.
  3. Examine solutions for improving coordination and communication within the multidisciplinary cancer care team and with patients/caregivers to improve outcomes for patients with mCSPC.

Faculty

Pedro Barata, MD, MSc
Assistant Professor, Deming Department of Medicine, Division of Hematology/Oncology, Genitourinary Cancers, Tulane University

Lisa M. Holle, PharmD, BCOP, FHOPA
Associate Clinical Professor, UConn School of Pharmacy
Associate Professor, UConn School of Medicine

ACCREDITED CONTINUING EDUCATION

Accreditation Statement

Jointly Accredited Provider Logo





In support of improving patient care, this activity has been planned and implemented by AXIS Medical Education and ACCC. AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

image


Credit Designation for Physicians
AXIS Medical Education designates this activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation for Pharmacists
This application-based activity is approved for 1.0 contact hour of continuing pharmacy education credit JA4008106-9999-21-021-L01-P.

Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hour.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

AXIS Contact Information
For information about the accreditation of this program, please contact AXIS at info@axismeded.org.

Disclosure of Conflicts of Interest

AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is t producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified and mitigated prior to initiation of the planning phase for an activity.

AXIS has mitigated and disclosed to learners all relevant conflicts of interest disclosed by  staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months:

Name of Faculty or Presenter/PlannerReported Financial Relationship
  

Pedro Barata, MD, MSc

Consultant (Institutional): Astellas, Dendreon, Eisai, EMD Serono, Pfizer, Inc., and Seattle Genetics

Contracted Research (Institutional): AstraZeneca

Research Grant (Institutional): BlueEarth Diagnostics 

Speaker's Bureau: Bayer and Caris

Lisa M. Holle, PharmD, BCOP, FHOPA 

Nothing to disclose

 

The directors, planners, managers and reviewers reported the following financial relationships they have with any ineligible company of any amount during the past 24 months:

Name of Planner/Manager/ReviewerReported Financial Relationship
  

Archana Ajmera, MSN, ANP-BC, AOCNP

Consultant: Janssen

Eric Castle, MD

Nothing to disclose

Marilyn Haas, PhD, RN, CNS, ANP-BC

Nothing to disclose

Lisa M Holle, PharmD, BCOP, FHOPA

Nothing to disclose

Dee Morgillo, MEd., MT (ASCP) CHCP

Nothing to disclose

Mary Stanley, MSW, PMP

Nothing to disclose 


Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Method of Participation and Request for Credit

  • Attend/participate in the educational activity and review all course materials.
  • Complete the CE Declaration form online by 11:59 PM ET on May 16, 2021. Instructions will be provided. If you do not enter the online portal by the above date, you will not be able to retrieve your statement of participation.  
  • Upon successful completion of the online form, your statement of completion will be presented to you to print. Pharmacists: your record will be automatically uploaded to CPE Monitor.

Speakers

Pedro C. Barata, MD, MSc

Assistant Professor of Medicine Hematology & Medical Oncology, Tulane University

Dr. Pedro Barata earned his medical degree from the New University of Lisbon in 2009 and completed his medical oncology training in 2016. Subsequently, he was invited to join the genitourinary group at Taussig Cancer Center, where he worked as a clinical fellow in genitourinary malignancies. Dr. Barata then moved to Tulane University to continue his clinical and research work in the GU field. Dr. Barata successfully expanded the genitourinary program offered at Tulane Cancer Center and he currently leads the kidney and bladder cancer program at Tulane University with a focus on clinical trials.  

 Dr. Barata has authored or co-authored more than 60 research publications in high-quality journals, such as Cancer, Annals of Oncology, and CA: Cancer journal Clinicians, with more than 700 scientific citations. He has presented multiple abstracts at important national and international meetings and has won multiple prestigious awards, including the Scholar-in-Training Award, AACR-NCI-EORTC Triple Meeting (2017) and the Annual Accelerating Anticancer Agent Development and Validation (AAADV) Program Scholarship (2018). He serves as a reviewer for prestigious peer-reviewed journals, such as JAMA Oncology, ASCO and Journal Global Oncology. 

Lisa M. Holle, PharmD, BCOP, FHOPA, FISOPP

Associate Clinical Professor of Pharmacy Practice, Department of Pharmacy Practice, UConn School of Medicine

Dr. Holle completed her Bachelor of Science in Pharmacy and post-baccalaureate Doctor of Pharmacy from the University of Wisconsin–Madison. She completed a specialized oncology residency at UT M.D. Anderson Cancer Center, and is a board-certified oncology pharmacist. Dr. Holle has worked as an oncology pharmacist for over 20 years in a variety of settings including private hospitals, academic medical centers, and medical communications. Currently, Dr. Holle is an Associate Clinical Professor at the UConn School of Pharmacy and Associate Professor at the UConn School of Medicine. Her practice site is at the UConn Health Carole and Ray Neag Comprehensive Cancer Center, where she works in a team-based ambulatory care clinic focusing on genitourinary and gastrointestinal cancers and in another team based-clinic focusing on hematologic malignancies.  

Dr. Holle is a Past President of HOPA and a past Secretariat member and Treasurer of the International Society of Oncology Pharmacy Practitioners (ISOPP). She is also an active member in many other professional oncology and pharmacy organizations. Dr. Holle’s clinical research program focuses on numeracy and patient decision-making, oncology quality improvement initiatives, medical marijuana, and oral anticancer therapy management.  

Event

Key:

Complete
Failed
Available
Locked
TxSCO
04/16/2021 at 1:00 PM (EDT)   |  60 minutes
04/16/2021 at 1:00 PM (EDT)   |  60 minutes
Emerging Therapies for the Management of Castration-Sensitive Prostate Cancer - Presented by the Texas Society of Clinical Oncology Feedback Survey
5 Questions
5 Questions We are glad you attended the Emerging Therapies for the Management of Castration-Sensitive Prostate Cancer - Presented by the Texas Society of Clinical Oncology. Your feedback will provide us with valuable information and allow us to design future programming that meets your professional needs. Thanks again for your participation!

How to Register

You must have a State Society or ACCC account to register for this event, which will enable you to register for future events and courses with just one click.

If You DO NOT Have an Account: 

  • To start, click the green “Register” button in the upper right corner of this page. You will be directed to “Your Cart.”
  • Click the green “Log In” button, then follow the proceeding steps, below. 

State Society and ACCC Members:

  • Click "Reset Password" and you will receive an email with a link to update your password. When your password is updated, you will be redirected to the “My Profile” page, where you can view and update your information.
  • If you do not receive an email or need assistance with resetting your password, please contact membership@accc-cancer.org.

Non-members:

  •  Click “Create Account.” Once your password is created, you will be redirected to the "My Profile" page, where you can view and update your information. Click “Change” to add your Areas of Concentration, then save your information.
  • Click “eLearning” at the top of your profile page to go back to the eLearning portal. In the box on the left side of the screen, click on the “Cart” link.
  • The green box in the upper right corner of this page will indicate “You are registered!” 

If You Have an Account: 

  • Please click the “Log In” button on the right side of this screen. You will be taken to the main login page that displays your email and password. 
  • Click the “Log in” button.
  • You will be automatically redirected back to the event page, and the green box in the upper right corner will say that “You are registered!” 

PRO TIP: If you save your password to your computer and remain logged in, you can register for additional events and courses in a matter of seconds—with just one click! 

For the best registration and viewing experience, please use Chrome, Edge, or Safari web browsers. Internet Explorer users may experience difficulties accessing the event. 

*If you are employed by a pharmaceutical/device manufacturer, consulting, or technology company, please contact  April Gascon for registration information. 

Once you complete your registration, you will receive an email from ACCC eLearning, which contains information on how to access this event. For assistance with registration or if you do not receive an email, please contact  registration@accc-cancer.org.

Already registered?
Log in to access.

Log In